Amikacin (15 mg/kg per day) was used in combination with cephalothin (7 gl m2 per day) as an empiric regimen for de novo febrile (>101°F [38.3°C]) episodes in 93 granulocytopenic (<1,000/mm3) cancer patients. Both drugs were given intravenously in four equal doses every 6 h. The response rate for all documented infections was 83%, including 11 of 17 (65%) bacteremias. Escherichia coli (14 cases) was the most common pathogen, whereas Pseudomonas aeruginosa (2 cases) caused fewer infections. Mean amikacin serum levels were 8.7
association with a bacteremia was a bad prognostic sign (only two of eight improving). Ototoxicity occurred in two (2%) patients, whereas presumed antibiotic-induced nephrotoxicity developed in six (7%) patients. Surveillance cultures (nose, gums axilla, and rectum) of all hospitalized patients revealed no significant change in the incidence of amikacin resistance. The combination of amikacin and cephalothin in this dose and schedule was safe and efficacious in these granulocytopenic patients.
Empiric treatment with broad-spectrum antibiotics is accepted therapy for de novo febrile episodes in granulocytopenic (granulocyte count, <1,000/mm3) cancer patients (5, 6, 17, 29) because 60 to 70% of these episodes are caused by documented infections. Prior to the appreciation that therapy in these patients had to be prompt, empiric, and with broad-spectrum antibiotics, gram-negative bacteremias were associated with a >90% mortality rate (5, 17) , and, overall, the mortality from infection was >50o (5, 6, 17, 29) . With current empiric treatment, 40 to 70% of these bacteremias and 70 to 80% of all documented infections respond to empiric broad-spectrum therapy (5, 6) . Such empiric therapy usually consists of an aminoglycoside in combination with cephalothin and/ or carbenicillin. Amikacin is a new aminoglycoside which has a spectrum similar to gentamicin but a lower incidence ofresistance among gram-negative bacilli. We felt that its use in granulocytopenic patients would frequently be necessary in instances wherein gentamicin resistance was encountered. We wished, therefore, to evaluate the combination of amikacin and cephalothin concerning efficacy and potential renal toxicity with a modified dose schedule designed to hopefully decrease nephrotoxicity.
MATERIALS AND METHODS
Requirements for protocol. Patients were eligible for the protocol if they had an absolute granulocyte count of <1,000/mm3 and a temperature of >101°F (38.3°C) in the absence of an obvious noninfectious cause of fever (e.g., the administration of blood products just before the fever). Patients with allergic histories to cephalothin or aminoglycosides were excluded.
Pretherapy evaluation. The following evaluation was made before antibiotic therapy: (i) complete history and physical examination with specific reference to subtle findings of inflammation (29) Antibiotic susceptibility -testing and serum levels. Antibiotic susceptibility testing of all isolated pathogens was performed by the Bauer-Kirby method (2), recommended by the Food and Drug Administration (9) . Amikacin-resistant, gram-negative bacilli were further evaluated by the microtiter technique to determine their minimal inhibitory concentration (MIC) (19) . Serum levels of amikacin were determined in selected patients at 1 and 5 h after completion of antibiotic infusion by the modified agar-well diffusion method described by Ben- nett et al. (3), using Bacillus subtilis as the assay organism and beta-lactamase to inactivate cephalothin.
RESULTS
Patient population. There were 93 patient drug trials (50 patients treated once, 9 patients treated two times, 4 patients treated three times, 2 patients treated four times, and 1 patient treated five times). Fifty-four were male and 39 were female. The mean age was 43 years. Patients' diagnoses were: acute leukemia, 66; solid tumors, 18; and lymphoma, 9. The average number of days that patients were granulocytopenic before therapy was 18 days, and the median initial granulocyte count was <100/mm3. Thirty-seven patients were responding to antitumor therapy, whereas 56 were not ("late stage"). Eleven of the 93 drug trials could not be evaluated for antibacterial antibiotic efficacy; four of these had documented viral infections and one had a documented fungal infection, and during six drug trials protocol violations occurred.
Susceptibility and serum levels. By disk susceptibility, 87% of the pathogens were susceptible to amikacin, whereas 85% were susceptible to cephalothin. Seventy-six percent were susceptible to both antibiotics, and only 4% (one Pseudomonas aeruginosa and one Escherichia coli) were resistant to both antibiotics. At 1 h, the mean amikacin serum level was 8.7 ,ug/ml (range, 6.1 to 10.8 ,ug/ml), and at 5 h it was 2.2 ,ug/ml (range, 1.2 to 5.3 ,g/ml). Side effects. Decreased hearing was clinically observed in two patients receiving this combination of antibiotic therapy; one of these patients had received amikacin for 35 days before her ototoxicity was noted. Audiograms (preinitiation and about 1 week post-therapy) were performed in 20 patients. None of these 20 audiograms showed any significant change.
Elevated serum creatinines (>1.5 mg/100 ml) occurred in 10 of the 93 patient trials, with initial creatinines of <1.5 mg/100 ml. This could be explained by shock in three cases and administration of amphotericin B in one. Six patients (7%) had no obvious cause other than drugs for their nephrotoxicity. Three developed intermediate drug-induced nephrotoxicity (rise to >1.5 but <2.5 mg/100 ml) and three had severe (rise to >2.5 mg/100 ml) nephrotoxicity (range, >2.5 to 4.3 mg/100 ml). Five of these six patients had normalization of their creatinine post-therapy. The other patient died from an infection as his creatinine remained elevated. With respect to age, 4% (3 of 77) <60 years old and 19% (3 of 16) >61 years old had drug-induced nephrotoxicity. All of the severe nephrotoxicities occurred in the younger age group.
Drug-related fever occurred in three patients. The following subsequent infections occurred in seven patients: (i) Torulopsis glabrata bacteremia; (ii) Aspergillus sp. pneumonia; (iii) resistant P. aeruginosa; (iv) susceptible P. aeruginosa; (v) susceptible E. coli bacteremia; (vi) susceptible K. pneumoniae bacteremia and T. glabrata septicemia; (vii) susceptible E. coli bacteremia and Candida albicans septicemia. All of these infections occurred in persistently granulocytopenic patients who were refractory to chemotherapy (0 of 37 chemotherapy responsive patients and 7 of 56 chemotherapy refractory patients developed subsequent infections). When one divides the refractory group into those who received <5 days of systemic antibiotics and >5 days, the number of days of granulocytopenia and degree of granulocytopenia are similar, but there were 0 of 23 patients in the group that received <5 days of antibiotics who developed a subsequent infec-VOL. 12, 1977 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHZMOTHER. tion, whereas there were 7 of 33 in the group that received >5 days of antibiotics. Five of these infections were ultimately fatal. One of these infections was an amikacin-resistant P. aeruginosa. DISCUSSION The overall response rate of 84% for this empiric antibiotic regimen compares favorably to other previously reported empiric antibiotic regimens (4, 6, 12, 13, 21, 25, 26, 28-31 faecalis, and E. coli infections than previously.
Furthermore, there were relatively few gramnegative pneumonias and proportionately more oral, sinus, and skin infections. Additionally, granulocyte transfusions were utilized earlier in this study than previously. When possible, WBC transfusions were given within the first 24 to 48 h, when a patient was suspected or proven to have gram-negative bacteremia or pneumonia, or both, in a setting of marked granulocytopenia expected by marrow examination to persist longer than 1 week. All these factors probably contributed, in some part, to our high response rate.
The dose schedule for amikacin of 15 mg/kg per day given intravenously in four equal doses (instead of the usually recommended two equal doses) achieved acceptable mean serum levels at 1 h, which were above the MIC level for >90% of previously reported hospital-isolated, gram-negative bacilli (11, 20) and for 70 to 80% of previously reported gentamicin-resistant, gram-negative bacilli (24, 30) . In only 1 patient, of our 16 tested, was the 1-h level below 7 ,ug/ml. Additionally, it should be noted that with intravenous administration, the 1-h serum level is approximately one-half the peak level (18) .
Toxicity with this regimen was not excessive. Although only 20 patients had base line and follow-up audiograms, none showed any change.
Nephrotoxicity in our present study was less frequent and less severe than has been recently reported for several other antibiotic trials (4, 6, 22, 23) , using comparable dose ofcephalothin and gentamicin, but was more frequent than the estimated incidence with a high dose (5 mg/kg per day) of gentamicin alone (7, 10, 15) . However, it is difficult to make a meaningful comparison ofthe incidences ofnephrotoxicities in these studies. Even with respect to the EORTC (6) study of which the BCRC was a member, a valid comparison with the present study cannot be made. Although the base line creatinines, underlying disease processes, mean patient age, percentage of bacteremias, and length of antibiotic administration were comparable in the past (6) and present study, other important factors were not. In the present study, there were less pneumonias, less serious infections in general, and, in particular, less P. aeruginosa and K. pneumoniae infections. Further, more frequent surveillance of renal function was performed during the present study; this is probably the most important reason that severe nephrotoxicity occurred less frequently, i.e., earlier alteration of amikacin dosage.
The incidence of subsequent infections with this present antibiotic regimen is comparable to that in our previous studies (6, 28, 29; Greene et al., Ann. Intern. Med. 78:825-826, 1973). All these subsequent infections occurred in patients who were refractory to chemotherapy and had been profoundly granulocytopenic for a long period of time. Additionally, none of these subsequent infections occurred in those patients who had received less than 5 days of antibiotic administration. Perhaps, not surprisingly, these patients with late-stage nonresponding tumors and persistent granulocytopenia tended to develop serious gram-negative bacillary (i.e., Pseudomonas and Klebsiella) or fungal (i.e., Aspergillus and T. glabrata) infections. The role of the cephalothin arnd amikacin in predisposing to these infections is suggested by the observation that the degree of granulocytopenia was similar in those receiving both short-(<5 days) and long-term antibiotics, but the incidence of subsequent infections was much higher in the long-term systemic antibiotic group.
The results of this noncontrolled evaluation show that the combination of amikacin and cephalothin is another effective empiric regimen for treatment of presumed infection in granulocytopenic patients, and that its toxicities are similar to other cephalosporin-aminoglycoside combinations. Because there were many E. coli bacteremias and few Pseudomonas spp., Serratia spp., and Klebsiella spp. bacteremias in our series, it is difficult to compare these results with our previous series or to other empiric antibiotic series. More information concerning the percentage ofemergence of amikacin-resistant organisms and more comparative studies of amikacin combination therapy versus other empiric regimens are needed before final recommendations can be made concerning the use of empiric therapies containing amikacin.
At present, there are many acceptable empiric regimens, and no one regimen has consistently been shown to be superior. The final choice of which regimen to be used on a specific medical ward should not be based solely upon the results of prior antibiotic trials. The particular underlying diseases of a population at risk, common sites of infection in this population, colonizing and infecting organisms and the patterns of susceptibility and resistance of these organisms should all be used in determining which empiric regimen would be the most suitable in any given situation. Although other regimens such as ticarcillin and gentamicin might be more appropriate in many patient situations, cephalothin and amikacin would be an acceptable regimen in a setting of a high incidence of gentamicin-resistant, gram-negative organisms and a low incidence of P. aeruginosa infections among granulocytopenic cancer patients.
